Clinical

Cardiology: less revascularisation with drug-eluting stents for saphenous vein graft lesions

Researchers report that, for rates of revascularisation at one year, drug-eluting stents (DES) appear to be superior to bare metal stents (BMS) in saphenous vein graft lesions.

The results of the ISAR-CABG (Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions) study were presented recently at the ACC.

“Out to 12 months, the need of revascularisation was reduced by about half with drug-eluting stents compared to bare metal stents, and, for safety parameters, drug-eluting stents were comparable to bare metal stents for stent thrombosis, death or myocardial infarction,” said presenter and investigator Julinda Mehilli, director of clinical research and data coordinating in the Intracoronary Stenting and Antithrombosis Research Centre (ISAR) at the German Heart Centre in Munich, Germany.

The multi-centre, randomised study was the largest to-date comparing DES to BMS in the saphenous vein.

Read more.

Bookmark and Share

Post a Comment

Enter this security code

Submit Comment for Moderation